1. Home
  2. FCNCA vs INSM Comparison

FCNCA vs INSM Comparison

Compare FCNCA & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FCNCA
  • INSM
  • Stock Information
  • Founded
  • FCNCA 1898
  • INSM 1988
  • Country
  • FCNCA United States
  • INSM United States
  • Employees
  • FCNCA N/A
  • INSM N/A
  • Industry
  • FCNCA Major Banks
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • FCNCA Finance
  • INSM Health Care
  • Exchange
  • FCNCA Nasdaq
  • INSM Nasdaq
  • Market Cap
  • FCNCA 25.0B
  • INSM 26.0B
  • IPO Year
  • FCNCA N/A
  • INSM 2000
  • Fundamental
  • Price
  • FCNCA $1,871.35
  • INSM $127.80
  • Analyst Decision
  • FCNCA Buy
  • INSM Strong Buy
  • Analyst Count
  • FCNCA 10
  • INSM 17
  • Target Price
  • FCNCA $2,338.40
  • INSM $137.40
  • AVG Volume (30 Days)
  • FCNCA 125.2K
  • INSM 3.0M
  • Earning Date
  • FCNCA 07-25-2025
  • INSM 08-07-2025
  • Dividend Yield
  • FCNCA 0.42%
  • INSM N/A
  • EPS Growth
  • FCNCA N/A
  • INSM N/A
  • EPS
  • FCNCA 169.70
  • INSM N/A
  • Revenue
  • FCNCA $8,984,000,000.00
  • INSM $398,105,000.00
  • Revenue This Year
  • FCNCA $0.47
  • INSM $28.23
  • Revenue Next Year
  • FCNCA $2.38
  • INSM $119.99
  • P/E Ratio
  • FCNCA $11.03
  • INSM N/A
  • Revenue Growth
  • FCNCA N/A
  • INSM 21.15
  • 52 Week Low
  • FCNCA $1,473.62
  • INSM $60.40
  • 52 Week High
  • FCNCA $2,412.93
  • INSM $128.48
  • Technical
  • Relative Strength Index (RSI)
  • FCNCA 39.30
  • INSM 85.01
  • Support Level
  • FCNCA $1,789.69
  • INSM $106.54
  • Resistance Level
  • FCNCA $1,926.19
  • INSM $128.48
  • Average True Range (ATR)
  • FCNCA 39.51
  • INSM 4.11
  • MACD
  • FCNCA -8.06
  • INSM 1.68
  • Stochastic Oscillator
  • FCNCA 29.46
  • INSM 97.41

About FCNCA First Citizens BancShares Inc.

First Citizens BancShares Inc is the bank holding company of First Citizens Bank and Trust Company. The company's segments include the General Bank, the Commercial Bank, SVB Commercial, and Rail. The General Bank segment delivers products and services to consumers and businesses through its extensive network of branches and various digital channels. The Commercial Bank segment provides financial services, including lending, leasing, and advisory, to small and mid-market businesses across various industries. The SVB Commercial provides financial services to innovators, investors, and venture firms. The Rail segment provides tailored leasing and financing for railcars and locomotives across North America. It generates the majority of its revenue from the General Banking segment.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: